Reference
Frost & Sullivan. Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan. Media Release : 1 May 2013. Available from: URL: http://www.frost.com
Rights and permissions
About this article
Cite this article
Combination drugs: the future of hep B & C treatment in Europe. PharmacoEcon Outcomes News 678, 11 (2013). https://doi.org/10.1007/s40274-013-0411-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0411-9